This is in accordance with previous reports that have demonstrated that TNF α gene expression in colorectal mucosa and high serum TNF levels can be used as a predictor for IFX therapy in ulcerative colitis and Crohn’s disease, respectively [92,93]. The gene discussed is TNF; the disease is Crohn disease.